173 related articles for article (PubMed ID: 33862419)
1. Increased proportion of CD20+ T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report.
Lee JK; Kwon S; Han JH; Yoon SE; Kim BJ; Kang ES
J Neuroimmunol; 2021 Jun; 355():577564. PubMed ID: 33862419
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fujino T; Saito Y; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
Ann Hematol; 2020 Sep; 99(9):2141-2148. PubMed ID: 32451711
[TBL] [Abstract][Full Text] [Related]
3. Changes in B and T-cell subsets and NMO-IgG levels after immunoglobulins and rituximab treatment for an acute attack of neuromyelitis optica.
de Andrés C; Teijeiro R; Saiz A; Fernández P; Sánchez-Ramón S
Neurologia; 2015 Jun; 30(5):276-82. PubMed ID: 24674779
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
Wang Y; Chang H; Zhang X; Yin L
Mult Scler Relat Disord; 2021 May; 50():102843. PubMed ID: 33609924
[TBL] [Abstract][Full Text] [Related]
5. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder.
Kim SH; Hyun JW; Kim HJ
Neurochem Int; 2019 Nov; 130():104347. PubMed ID: 30513364
[TBL] [Abstract][Full Text] [Related]
6. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders.
Ciron J; Audoin B; Bourre B; Brassat D; Durand-Dubief F; Laplaud D; Maillart E; Papeix C; Vukusic S; Zephir H; Marignier R; Collongues N;
Rev Neurol (Paris); 2018 Apr; 174(4):255-264. PubMed ID: 29606320
[TBL] [Abstract][Full Text] [Related]
7. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy.
Ayzenberg I; Kleiter I; Schröder A; Hellwig K; Chan A; Yamamura T; Gold R
JAMA Neurol; 2013 Mar; 70(3):394-7. PubMed ID: 23358868
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20
Jiang B; Ke X; Zhang Q; Xu W; Su H; Huang J; Zhang M; Wang H; Jin C; Zhu J; Liu L; Cai Z; Zhao X; Zhou J; Zhang X; Liu J; Zhou H; Yu J; Sun X; Qi J; Qiu L
Sci Rep; 2020 Jul; 10(1):11676. PubMed ID: 32669656
[TBL] [Abstract][Full Text] [Related]
9. Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up.
Evangelopoulos ME; Andreadou E; Koutsis G; Koutoulidis V; Anagnostouli M; Katsika P; Evangelopoulos DS; Evdokimidis I; Kilidireas C
J Neurol Sci; 2017 Jan; 372():92-96. PubMed ID: 28017256
[TBL] [Abstract][Full Text] [Related]
10. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
[TBL] [Abstract][Full Text] [Related]
12. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
13. Peripheral CD19
Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of rituximab treatment for neuromyelitis optica.
Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 monoclonal antibodies: beyond B-cells.
Avivi I; Stroopinsky D; Katz T
Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
[TBL] [Abstract][Full Text] [Related]
16. Individualized rituximab treatment for relapsing neuromyelitis optica: a pediatric case report.
He D; Yu Y; Yan W; Dai Q; Xu Z; Chu L
Pediatr Neurol; 2014 Aug; 51(2):255-8. PubMed ID: 25079575
[TBL] [Abstract][Full Text] [Related]
17. Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab.
Mealy MA; Levy M
J Neuroimmunol; 2015 Oct; 287():29-30. PubMed ID: 26439958
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.
Gao F; Chai B; Gu C; Wu R; Dong T; Yao Y; Zhang Y
BMC Neurol; 2019 Mar; 19(1):36. PubMed ID: 30841862
[TBL] [Abstract][Full Text] [Related]
19. 20 years of rituximab treatment: what have we learnt?
Renner C
Future Oncol; 2019 Dec; 15(36):4119-4121. PubMed ID: 31718346
[No Abstract] [Full Text] [Related]
20. Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus.
Nasir S; Kerr DA; Birnbaum J
Arch Neurol; 2009 Sep; 66(9):1160-3. PubMed ID: 19752308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
